IO Biotech Faces Delisting Concerns
Ticker: IOBT · Form: 8-K · Filed: Dec 27, 2024 · CIK: 1865494
| Field | Detail |
|---|---|
| Company | Io Biotech, Inc. (IOBT) |
| Form Type | 8-K |
| Filed Date | Dec 27, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
TL;DR
IO Biotech might get delisted, stock watch!
AI Summary
IO Biotech, Inc. filed an 8-K on December 27, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, incorporated in Delaware with its principal executive offices in Copenhagen, Denmark, is subject to this reporting requirement.
Why It Matters
This filing indicates potential issues with IO Biotech's continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's ability to remain publicly traded.
Key Numbers
- 001-41008 — SEC File Number (Identifies the company's filing history with the SEC.)
- 87-0909276 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- IO Biotech, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Copenhagen, Denmark (location) — Principal Executive Offices
- December 26, 2024 (date) — Date of earliest event reported
- December 27, 2024 (date) — Date of Report (Date of earliest event reported)
FAQ
What specific listing rule or standard has IO Biotech failed to satisfy?
The filing does not specify the exact rule or standard that IO Biotech has failed to satisfy, only that a notice has been issued.
What is the expected timeline for any potential delisting action?
The filing does not provide a specific timeline for any potential delisting action.
Has IO Biotech taken any steps to address the listing deficiency?
The filing does not mention any specific steps taken by IO Biotech to address the deficiency.
What is the significance of the 'Date as of Change' being December 27, 2024?
This date indicates when the information in the filing became effective or was updated, aligning with the filing date.
Does this filing indicate an immediate delisting, or is it a preliminary notice?
This filing is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard,' suggesting it is a notification of a potential issue rather than an immediate delisting.
Filing Stats: 781 words · 3 min read · ~3 pages · Grade level 13.4 · Accepted 2024-12-27 16:16:29
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share IOBT The Nasdaq
- $1.00 — Company's common stock had fallen below $1.00 per share for 30 consecutive trading da
Filing Documents
- d903966d8k.htm (8-K) — 24KB
- 0001193125-24-285936.txt ( ) — 143KB
- iobt-20241226.xsd (EX-101.SCH) — 3KB
- iobt-20241226_lab.xml (EX-101.LAB) — 17KB
- iobt-20241226_pre.xml (EX-101.PRE) — 11KB
- d903966d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IO Biotech, Inc. Date: December 27, 2024 By: /s/ Mai-Britt Zocca Mai-Britt Zocca, Ph.D. Chief Executive Officer